Compare eBay Inc (EBAY) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs Incyte Corporation — how do they compare? eBay Inc trades at $102.34 (market cap $47.17B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: eBay Inc is the larger of the two by market cap, and eBay Inc pays a 1.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| EBAY | INCY | |
|---|---|---|
Market Cap | $47.17B | $24.54B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $129.93 |
52-Week Low | $79.41 | $81.61 |
Enterprise Value | $51.00B | $20.04B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $102.23, down 5.09% amid reports GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals with support near $104, while fundamentals remain solid with Q2 2026 earnings beating estimates and an 18.57% net income margin. Revenue growth is projected to reach $12.0 billion in 2026, though cash flow turned negative in 2025.
The outlook is mixed: strong execution and a potential partnership or buyout offer present upside, but withdrawal of the bid and insider selling pose near-term risks. Analyst consensus is a $119.31 price target with a buy rating, but investors face volatility from deal uncertainty and competitive pressures in e-commerce.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
